Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival compared with best supportive care after chemotherapy in patients with resected stage II-IIIA non-small cell lung cancer (NSCLC), according to the results of the IMpower010 study presented at the 2021 virtual American Society of Clinical Oncology (ASCO) annual meeting.
In this exclusive MedPage Today video, Nicholas Rohs, MD, of the Icahn School of Medicine at Mount Sinai in New York City, discusses his issues with the study design, but why he still believes the results are meaningful.
